We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Elevated Serum DDE and Risk for Alzheimer Disease

Alfred Bernard, PhD1
[+] Author Affiliations
1Catholic University of Louvain, Brussels, Belgium
JAMA Neurol. 2014;71(8):1055-1056. doi:10.1001/jamaneurol.2014.432.
Text Size: A A A
Published online


To the Editor I read with great interest the article by Richardson and colleagues1 showing that the diagnosis and severity of Alzheimer disease (AD) were both associated with elevated serum levels of dichlorodiphenyldichloroethylene (DDE), the main metabolite of dichlorodiphenyltrichloroethane (DDT). The authors also showed that DDE and DDT increase the release of amyloid precursor protein in cultures of human neuroblastoma cells, which gives a mechanistic plausibility to their observations, although this effect (amyloid precursor protein release increased by almost 50%) was found at DDE/DDT levels more than 1 order of magnitude greater than in patients with AD. I think these findings should be interpreted with caution. The main reason is that they were based on DDE serum concentrations that were not adjusted for several important confounders.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





August 1, 2014
Jason R. Richardson, PhD; Allan I. Levey, MD, PhD; Dwight C. German, PhD
1Department of Environmental and Occupational Medicine, Rutgers Robert Wood Johnson Medical School, Piscataway, New Jersey
2Department of Neurology and Alzheimer’s Disease Research Center, Emory University, Atlanta, Georgia
3Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas
JAMA Neurol. 2014;71(8):1056. doi:10.1001/jamaneurol.2014.1548.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

1 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...